showed that crizotinib effectively reduced leukemia cell burden in patients with ALK-rearranged AML and pediatric AML harboring the RAN-binding protein 2-anaplastic lymphoma kinase fusion gene (64, 65). The gene discussed is RANBP2; the disease is acute myeloid leukemia.